Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC105 with Abiraterone or Enzalutamide in mCRPC
NCT03418324Phase 2Completed
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Mar 2018
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of carotuximab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Cedars-Sinai Medical Center. Started Mar 2018; status: completed.
02
Drugs
carotuximab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03418324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03418324.